Building Strategic Liquid Biopsy Partnerships to Accelerate LBx/CDx Success in Precision Oncology
- Gain a clear overview of the evolving liquid diagnostic partnership landscape, and how leading Dx players are positioning themselves across drug development programs
- Understand how strategic collaborations between biopharma and liquid biopsy partners are structured to align assay capability, regulatory strategy and commercial objectives
- Explore what differentiates high-value liquid Dx partners today, and how to select and manage partnerships that accelerate companion diagnostic readiness and clinical impact